Sanofi (EPA: SAN)

France flag France · Delayed Price · Currency is EUR
90.78
-0.02 (-0.02%)
Nov 21, 2024, 9:14 AM CET
6.27%
Market Cap 113.83B
Revenue (ttm) 48.45B
Net Income (ttm) 4.51B
Shares Out 1.25B
EPS (ttm) 3.59
PE Ratio 25.30
Forward PE 10.83
Dividend 3.76 (4.12%)
Ex-Dividend Date n/a
Volume 55,863
Open 90.44
Previous Close 90.80
Day's Range 90.42 - 90.94
52-Week Range 83.28 - 106.14
Beta 0.42
Analysts n/a
Price Target n/a
Earnings Date Oct 25, 2024

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric ... [Read more]

Sector Healthcare
Founded 1994
Employees 86,088
Stock Exchange Euronext Paris
Ticker Symbol SAN
Full Company Profile

Financial Performance

In 2023, Sanofi's revenue was 46.03 billion, an increase of 1.42% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.

Financial Statements

News

Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase

Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.

2 days ago - CNBC International TV

Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase

Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.

3 days ago - CNBC

Vaccine stocks hit by Robert Kennedy Jr nomination

GSK, Sanofi and Moderna shares all sink after Donald Trump chooses vaccine sceptic as top US health official

5 days ago - Financial Times

European And US Vaccine Stocks Are Under Pressure - Here's WHy

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.

5 days ago - Benzinga

European Stocks Fall as Traders Trim Rate-Cut Bets; Sanofi Drops

European stocks fell as traders pared back expectations for an interest-rate cut by the Federal Reserve in December after cautious comments from Chair Jerome Powell.

6 days ago - BNN Bloomberg

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More...

6 days ago - GlobeNewsWire

Telangana attracted 141 life sciences investments worth Rs 36,000 crore in 1 year: Sridhar Babu

Telangana has secured 141 life sciences investments totaling nearly ₹36,000 crore in the past year, creating thousands of jobs. Major players like Cigna, Amgen, and Sanofi are establishing GCCs and in...

6 days ago - The Times of India

Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom

A new 13F filing from Viking Fund Management reveals which companies the fund bought and sold in the third quarter, including exiting some oil companies ahead of the 2024 election. Third Quarter Exits...

6 days ago - Benzinga

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with ...

6 days ago - GlobeNewsWire

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA’s (NASDAQ: SNY...

7 days ago - Benzinga

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024

― Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalen...

8 days ago - Benzinga

Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform

CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indicatio...

8 days ago - Business Wire

RFK Jr.'s Impact on Healthcare Policy: Investors Weigh Risks and Opportunities

Emily Field from Barclays and Lance Wilks share insights on how RFK Jr.'s influence could affect stocks in the pharmaceutical and healthcare sectors, including companies like GSK, Sanofi, and Novo Nor...

8 days ago - CNBC

CEO of pharma giant Sanofi says businesses should stop ‘AI washing’

Some companies are overselling AI without thinking through the risks, according to Paul Hudson

9 days ago - Fortune

The Accumulus Platform Powers Sanofi's Submissions to Multiple Regulators Around the World

BURLINGAME, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc. (“Accumulus”), is revolutionizing the scalability of reliance pathways, enabling a recent submission from Sanofi to multip...

13 days ago - GlobeNewsWire

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on D...

15 days ago - GlobeNewsWire

SandboxAQ CEO on the firm's partnership with Sanofi

Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical development.

16 days ago - CNBC International TV

SandboxAQ CEO on the firm's partnership with Sanofi

Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical development.

16 days ago - CNBC

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Successful closing of exclusive worldwide licensing agreement with Sanofi for three potential best-in-class clinical-stage dual-masked T-cell engagers with initial clinical data anticipated in Q1 20...

20 days ago - Benzinga

Novavax Q3 Earnings A Week Away - Time To Accept A New Reality

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock valuation will fall over time. Learn more on NVAX stock here.

20 days ago - Seeking Alpha

Sanofi Cancels Consumer Healthcare Business Spin-Off

On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83, Market Cap: $136.6 billion, EN Paris: SAN FP, €100.04, Market Cap: €126.9 billion) announced that it has entered into exclusive negotiations ...

21 days ago - Forbes

Resalis Therapeutics Gains Strategic Equity Investment from Sanofi

TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead invest...

24 days ago - Business Wire

Why Sanofi Stock Flew Higher on Friday

No investor can ignore a crushing bottom-line beat and raised profitability guidance.

26 days ago - The Motley Fool